Qualification Advantages
Hibisure has independent research and development, manufacturing, and quality inspection departments, and its products have successively obtained registration and certification from China's CFDA, EU CE, and US FDA.
Company Profile
Development History
2017Year3Month
Found in Suzhou
Patent for Total Respiratory Drug Delivery System filed via PCT in 2016;
Invested by Suzhou High-Tech Investment Group in December 2017.
2019Year5Month
Launched the BN series products
BNs launched for inhalation therapy of lower respiratory tract and sinusitis
2022Year12Month
Million units milestone
Annual domestic and overseas sales exceeded 1,000,000 units for the first time;
Added 65,000 square feet of production base in Jiangning District, Nanjing.
2023Year5Month
Launched the BO and BV series products
BOs launched for oxygen therapy;
BVs launched for OSAS and COPD.
2024Year12Month
BOV products enter clinical trials
Product combining BO, BV core functions enters clinical trials.
